Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Pacira BioSciences enters its October 30 earnings print with a persistent short overhang, a live activist on the register, and a Street that is cautiously turning more constructive, a combination that sets up a genuinely interesting next three weeks.
Short interest is the dominant feature of the positioning picture, and it has been building. At 18% of the free float, PCRX ranks squarely in the high-conviction short camp. That figure has risen roughly 6% over the past month, with the bulk of the climb coming gradually rather than in a single spike, suggesting methodical accumulation rather than a squeeze or forced cover. The ORTEX short score of 71.8 sits near its highest level of the recent range, having peaked around 74 in late September before easing slightly this week. What cuts against the short thesis structurally is the borrow market: availability is running at 333%, meaning there are more than three shares available to borrow for every one already borrowed. Cost to borrow is 0.52%, low by any standard. Shorts can add freely without paying a premium, which removes one of the typical pressure valves. Options positioning adds little urgency in either direction. The put/call ratio of 0.53 sits fractionally above its 20-day average and well inside the year's range of 0.16 to 0.96. There is no evidence of a defensive hedging surge ahead of the print.
The Street has grown more constructive in recent weeks, though the picture remains split. Oppenheimer initiated with an Outperform and a $32 target in late September. Truist raised its target to $31 this week while holding a Buy. Needham has the highest published target at $33. Against that, Leerink Partners initiated at Market Perform with a $28 target in early September, and RBC holds a Sector Perform at $25. The consensus rating is Buy, with a mean price target around $30, roughly 21% above the current price of $24.76. The stock has dropped 6% over the past month and 3.5% this week, widening the gap to targets. Forward earnings expectations are a genuine bright spot: the eps_12m_fwd_yoy_increase factor scores in the 90th percentile of the universe, reflecting a meaningful recovery in what analysts expect from the business over the next year. The analyst_rec_diff factor ranks in the 92nd percentile, suggesting recent recommendation changes have skewed positive relative to peers. The EV/EBITDA multiple has edged lower over the past 30 days, now at 5.6x, which is undemanding for a pharma franchise of this scale.
The bull and bear debate centres almost entirely on EXPAREL's reimbursement durability. Bulls point to UnitedHealth separately reimbursing EXPAREL outside the surgical bundle for around 40 million covered lives, the NOPAIN Act tailwinds, and 2026 revenue guidance of $745 million to $770 million in total as evidence that the core franchise has more runway than the short thesis allows. The April 2025 patent settlement, which potentially extends exclusivity to 2044, is the structural backstop. Bears focus on the cliff after December 31, 2027, when current reimbursement support may weaken, the limited near-term offset from pipeline assets (PCRX-201 is still in Phase 2 with a year-end 2026 data readout, which is itself a binary event within the next three months), and the $24 million ZILRETTA and iovera revenues that have not demonstrated meaningful portfolio synergy.
The most newsworthy structural feature of PCRX is the activist presence. Pedro Escudero holds a Schedule 13D position, meaning he has filed with activist intent. His stake was last disclosed at 7.3% of the class, up from 6.83% at the prior filing in March 2026. He first filed in August 2025 and has now amended four times. The disclosure caveat applies: stakes are as-last-disclosed around the 5% threshold, and a holder can fall below 5% without filing again. But the direction of travel in Escudero's filings has been upward, and a 13D holder who has been amending quarterly bears watching. BlackRock holds 16.8% as the largest institutional holder and added shares in the most recent reported period. State Street and Dimensional both added modestly. Vanguard trimmed. Insider activity has been limited to planned sales under 10b5-1 programmes and routine compensation grants, nothing that reads as discretionary conviction in either direction.
The earnings history is worth flagging plainly. After the August 2026 print, the stock fell 7.6% the next day and extended that to a 9.4% loss over the following five sessions. The prior release saw a much smaller one-day move but also drifted lower over the week. The direction of both recent reactions was negative. With October 30 now 23 days away, the question heading into the print is whether the EXPAREL reimbursement commentary can shift the narrative that has been driving both the short build and the downward price drift of the past month.
See the live data behind this article on ORTEX.
Open PCRX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
